^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer

Excerpt:
...all KRAS mutant variants were associated with resistance to sunitinib treatment.
DOI:
10.1007/s00432-013-1401-9